Vaccinations save lives.

RECOMBITEK, for the protection of canines.

The RECOMBITEK family of vaccines have been proven safe and effective to protect puppies and dogs from a variety of diseases. For some vaccines, extensive research and the use of advanced science (recombinant technology) may help protect your pet without adjuvants and the potential risks of those adjuvants. Learn more about recombinant vaccines here.

RECOMBITEK Distemper
  • RECOMBITEK C3 (rDAP)
  • RECOMBITEK C4 (rDAPP)
  • RECOMBITEK C4/CV (rDAPPC)
  • RECOMBITEK C6 (rDAPP-LCI)
  • RECOMBITEK C6/CV (rDAPPC-LCI)
  • RECOMBITEK C7 (rDAP-LCGIP)
  • RECOMBITEK C8 (rDAPP-LCGIP)

Recombinant-vectored vaccine for targeted protection.

Through the advanced technology of Type 3 recombinant vaccine manufacturing, RECOMBITEK rDistemper offers safe, proven, efficacious distemper protection for your canine patients19

  • Contains both the HA (hemagglutinin) and F (fusion membrane protein) antigens
  • Used throughout North America and South America, including highly endemic are of Mexico and Brazil
RECOMBITEK 4Lepto

RECOMBITEK Lepto protects against causative agents of canine leptospirosis.20

  • Protects against shedding spirochetes that transmit disease
  • Following a virulent challenge 15.5 months after the second vaccation 100% of vaccinates were protected fromLeptospira grippotyphosa even when vaccinates were commingled with control dogs actively shedding spirochetes
  • Non-adjuvanted
RECOMBITEK Lyme

Targeted protection through recombinant technology.

By using only pure outer surface protein A (OspA), RECOMBITEK Lyme provides efficacy without the potentially harmful flagellan protein.15 Plus, RECOMBITEK Lyme contains no chemical adjuvants, thus reducing the potential risk typically associated with adjuvants.

  • Recombinant subunit technology uses only a pure non-adjuvanted protein to stimulate immunity
  • In one study, shown to completely block transmission of Lyme disease spirochete18
  • Not a whole cell bacteria
RECOMBITEK Canine Parvo

Powerful protection for puppies.

RECOMBITEK Canine Parvo helps close the window of vulnerability to canine parvovirus (CPV), even in puppies born with high levels of maternal antibodies. While declining levels of maternal antibodies may not protect puppies from viral infection, they may interfere with the effectiveness of a vaccine. RECOMBITEK Canine Parvo breaks through maternal antibodies to provide safe, proven, powerful protection.

  • Proven protection against CPV by 12 weeks of age21
  • High-titer, low-passage profile helps break through maternal antibodies
  • Protects against CPV2a and CPV2b
  • Millions of doses sold throughout North America and South America1
RECOMBITEK Canine Corona-MLV

The only modified-live corona vaccine available

RECOMBITEK Corona MLV is the only modified-live, canine-origin coronavirus available today, providing early rapid protection against canine coronavirus (CCV).

  • Prevents intestinal damage22
  • Prevents shedding of virulent virus22
  • No virus isolated in over 90% of small intestine samples22
  • Rapid, early protection against clinical signs of CCV22
RECOMBITEK Canine Parvo + Corona-MLV

RECOMBITEK Canine Parvo + Corona-MLV combines the benefits of RECOMBITEK Canine Parvo and RECOMBITEK Canine Corona-MLV in one vaccine.

RECOMBITEK Vaccines Portfolio
Vaccines Desiccants Diluent
RECOMBITEK® C3 (rDAP) 25 x 1 dose/1mL dose Distemper — canarypox-vectored recombinant Adenovirus — MLV, type 2 Parvovirus — MLV, low-passage, high-titer Sterile Water
RECOMBITEK C4
(rDAPP)
25 x 1 dose/1mL dose
Distemper — canarypox-vectored
recombinant
Adenovirus — MLV, type 2
Parainfluenza — MLV
Parvovirus — MLV, low-passage,
high-titer
Sterile Water
RECOMBITEK C4/CV (rDAPPC) 25 x 1 dose/1mL dose Distemper — canarypox-vectored recombinant Adenovirus — MLV, type 2 Parainfluenza — MLV Parvovirus — MLV, low-passage, high-titer Coronavirus — MLV Sterile Water
RECOMBITEK C6 (rDAPP-LCI) 25 x 1 dose/1mL dose Distemper — canarypox-vectored recombinant Adenovirus — MLV, type 2 Parainfluenza — MLV Parvovirus — MLV, low-passage, high-titer Leptospira — killed, L. canicola and L. icterohaemorrhagiae
RECOMBITEK C6/CV (rDAPPC-LCI) 25 x 1 dose/1mL dose Distemper — canarypox-vectored recombinant Adenovirus — MLV, type 2 Parainfluenza — MLV Parvovirus — MLV, low-passage, high-titer Coronavirus — MLV Leptospira — killed,
L. canicola and
L. icterohaemorrhagiae

RECOMBITEK C7 (rDAP-LCGIP)

25 x 1 dose/1mL dose

Distemper – canarypox-vectored recombinant
Adenovirus – MLV, type 2

Parvovirus – MLV, low-passage, high-titer

Leptospira – killed,

L. canicola, L. grippotyphosa, L. icterohaemorrhagiae and L. pomona

RECOMBITEK C8 (rDAPP-LCGIP)

25 x 1 dose/1mL dose

Distemper – canarypox-vectored recombinant
Adenovirus – MLV, type 2
Parainfluenza – MLV

Parvovirus – MLV, low-passage, high-titer

Leptospira – killed,

L. canicola, L. grippotyphosa, L. icterohaemorrhagiae and L. pomona
RECOMBITEK 4 Lepto
(LCGIP)

50 x 1 dose/1mL dose
None Leptospira — killed,
L. canicola, L. grippotyphosa,
L. icterohaemorrhagiae and
L. pomona
RECOMBITEK Lyme
(rLyme)

50 x 1 dose/1mL dose
20 x 1 dose/1mL dose
None Lyme — recombinant,
OspA from Borrelia
burgdorferi spirochete
RECOMBITEK Canine
Parvo (CPV)

50 x 1 dose/1mL dose
None Parvovirus — MLV,
low-passage, high-titer
RECOMBITEK Canine
Corona-MLV (CCV)

25 x 1 dose/1mL dose
Coronavirus — MLV Sterile Water
RECOMBITEK Canine
Parvo + Corona-MLV

(CPV + CCV)
25 x 1 dose/1mL dose
Coronavirus — MLV Parvovirus — MLV,
low-passage, high-titer

What is recombinant technology?23,24

Traditionally, vaccines are made by killing or attenuating the disease-causing pathogen and injecting it into the patient to trigger the patient's immune system to produce antibodies or activated T-cells for protection against the disease. Then, if the patient comes in natural contact with the disease-causing virus or bacteria, the body's immune system is already primed to recognize the specific organism invader and armed to fight it off.

Recombinant vaccine, such as Recombitek Distemper, consists of a carrier or vector that carries a small portion of the genetic material of the disease-causing virus. When introduced (and expressed) in the patient's body, recombinant vaccines can trigger robust protective immunity targeting the pathogenic organism. Because only genetic fragments, and not the complete pathogenic organism, are incorporated into the vector, it is not possible for the recombinant vaccine to produce active disease in the vaccinated animal.

REFERENCES: 18. Conlon JAR, et al. "Efficacy of a nonadjuvanted, outer surface protein A, recombinant vaccine in dogs after challenge by ticks naturally infected with Borrelia burgdorferi.".19. Pardo MC, Tanner P,Bauman J,et al. Immunization of puppies in the presence of maternally derived antibodies against canine distemper virus. J Comp Path.2007;147:S72-S75.20. RECOMBITEK 4 Lepto Product Label. 21. RECOMBITEK Canine Parvo Product Label. 22. Pardo MC, Mackowiak M. Efficacy of a new canine-origin, modified-live virus vaccine against canine coronavirus. Canine Practice. 1999;24:6-8. 23. National Institute of Allergy and Infectious Diseases. Types of vaccines. http://www.niaid.nih.gov/topics/ vaccines/understanding/pages/typesvaccines.aspx. Accessed March 29, 2015. 24. Taylor J, et al. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine. 1995;13(6):539-549.